common.study.topics.clinical

Visual Changes and Retinal Vein Occlusion and Macular Edema

common.study.values.description

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Brolucizumab 6 mg

Solution for injection (intravitreal use)

Drug - Aflibercept 2 mg

Solution for injection (Intravitreal use)

Sham injection

Empty sterile syringe without a needle administered as a sham injection for masking purposes

participant.views.study.view.additional

participant.views.study.view.scientific-title

An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

common.study.values.clinical-trial-id

NCT03802630

participant.views.study.view.id

bqx6Ra